Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B

Table 2 Clinical characteristics of patients with hepatitis B according to serum PAF-AH percentiles

Variable	Group 1	Group 2	Group 3	Group 4	P- value
PAF-AH (U/L)	>1053	709-1053	477-708	< 477
Female/male	14/40	13/40	25/30	18/36	0.077
Age (year)	44.6 ± 12.4	42.3 ± 12.5	45.1 ± 13.6	45.9 ± 16.1	0.574
BMI (kg/m²)	22.8 ± 3.6	22.8 ± 2.5	22.7 ± 2.3	23.0 ± 3.5	0.248
TBIL (μmol/L)	337.4 ± 206.9	139.1 ± 161.9	85.6 ± 148.3	59.1 ± 137.2	<0.001
TBA (μmol/L)	151 ± 79	110 ± 99	51 ± 56	37 ± 59	<0.001
ALT (U/L)	365 ± 456	507 ± 699	333 ± 454	243 ± 374	0.067
AST (U/L)	276 ± 264	223 ± 280	174 ± 201	121 ± 150	<0.001
ChE (U/L)	3766 ± 1905	4400 ± 2631	5000 ± 2716	5470 ± 2436	0.003
TG (mmol/L)	1.68 ± 0.94	1.35 ± 0.90	1.19 ± 0.59	1.04 ± 0.89	<0.001
Tch (mmol/L)	3.11 ± 1.48	3.51 ± 1.76	3.37 ± 1.23	2.94 ± 0.90	0.147
HDL-c (mmol/L)	0.22 ± 0.37	0.54 ± 0.49	0.69 ± 0.43	0.83 ± 0.44	<0.001
LDL-c (mmol/L)	1.28 ± 0.97	1.73 ± 0.91	1.80 ± 0.70	1.53 ± 0.57	0.005
ApoAI (g/L)	0.30 ± 0.27	0.60 ± 0.35	0.79 ± 0.40	0.85 ± 0.37	<0.001
ApoB (g/L)	0.82 ± 0.34	0.73 ± 0.31	0.67 ± 0.21	0.53 ± 0.16	<0.001
Cr (μmol/L)	89 ± 69	87 ± 84	94 ± 104	70 ± 13	0.323
Glu (mmol/L)	4.49 ± 1.84	5.67 ± 2.87	5.16 ± 1.57	4.86 ± 1.97	0.015
PT (s)	20.5 ± 9.4	17.2 ± 7.6	13.8 ± 3.9	13.9 ± 4.3	<0.001
MELD score	20.7 ± 9.9	14.0 ± 9.1	10.1 ± 8.2	7.0 ± 5.5	<0.001
Mortality (yes/no)	17/37	10/43	6/49	1/53	<0.001
CSHB (yes/no)	35/19	8/45	5/50	1/53	<0.001

ISSN: 1476-511X